41st week of 2012 patent applcation highlights part 39 |
Patent application number | Title | Published |
20120258896 | ZINC DITHIOCARBAMATE LUBRICATING OIL ADDITIVES - A lubricating oil composition comprising a zinc dithiocarbamate fraction, for use in a gasoline or diesel engine equipped with fluoroelastomer seals, wherein said zinc dithiocarbamate fraction consists essentially of zinc dithiocarbamate molecules per Formula I:
| 2012-10-11 |
20120258897 | CYLINDER LUBRICATING OIL COMPOSITION FOR CROSSHEAD-TYPE DIESEL ENGINE - The present invention provides a cylinder lubricating oil composition for a crosshead-type diesel engine, which is improved in oxidation stability and anti-scuffing properties besides the properties of the conventional cylinder lubricating oil composition and comprises a base oil having an aromatic content of 8.5 percent by mass or more and on the basis of the total mass of the composition (A) an alkaline earth metal phenate in an amount of 0.005 mole/kg or more on the basis of phenate soap content, (B) an aminic antioxidant in an amount of 0.1 to 5 percent by mass and (C) an oil-soluble molybdenum compound in an amount of 30 to 500 ppm by mass on the basis of molybdenum and having a base number of 20 to 100 mgKOH/g and a 100° C. kinematic viscosity of 12.6 mm | 2012-10-11 |
20120258898 | SYSTEM LUBRICATING OIL COMPOSITION FOR CROSSHEAD-TYPE DIESEL ENGINE - The present invention provides a system lubricating oil composition for a crosshead-type diesel engine, which can prevent fuel efficiency deterioration by suppressing the viscosity increase and comprises a mineral base oil and/or a synthetic base oil, (A) (a-1) a star polymer having a vinyl aromatic hydrocarbon structure in the molecule and/or (a-2) an ethylene-α-olefin copolymer or a hydrogenated compound thereof and having a base number of 4 to 20 mgKOH/g and a 100° C. kinematic viscosity of 7.5 to 15.0 mm | 2012-10-11 |
20120258899 | USE OF COMB COPOLYMERS FOR IMPROVING SCUFFING LOAD CAPACITY - The present invention relates to the use of comb polymers comprising, in the main chain, repeat units derived from polyolefin-based macromonomers with a molecular weight of at least 500 g/mol, and repeat units derived from low molecular weight monomers with a molecular weight less than 500 g/mol, for improving the load-bearing capacity of hydraulic fluids. Furthermore, the present invention describes new hydraulic fluids. | 2012-10-11 |
20120258900 | DETERGENT COMPOSITIONS CONTAINING BACILLUS SUBTILIS LIPASE AND METHODS OF USE THEREOF - The present compositions and methods relate to a lipase cloned from | 2012-10-11 |
20120258901 | CONCENTRATED FILM DELIVERY SYSTEMS - A water soluble strip that includes a carrier film that include water soluble polymer, one or more actives and one or more agents such as heat forming agent and/or degrading accelerator. The water soluble strip can optionally include other additives. The actives includes antimicrobial agent, cleaning agent and/or surfactant. The water soluble strip can include other materials. The heat forming agent and/or degrading accelerator, when used, are designed facilitate in degrading or dissolving the water soluble strip and/or increase the activity of the one or more actives. The water soluble film can be used for a variety of applications such as a hard surface cleaning strip, dishwashing strip, laundry cleaning strip, stop removing strip, drain unclogging strip, toilet bowl cleaning strip and the like. The water soluble strip eliminates the need to purchase and store numerous containers and/or heavy containers of cleaner that take up large amounts of shelf space. | 2012-10-11 |
20120258902 | CONCENTRATED FILM DELIVERY SYSTEMS - A water soluble strip that includes a carrier film that include water soluble polymer, one or more actives and one or more agents such as heat forming agent and/or degrading accelerator. The water soluble strip can optionally include other additives. The actives includes antimicrobial agent, cleaning agent and/or surfactant. The water soluble strip can include other materials. The heat forming agent and/or degrading accelerator, when used, are designed facilitate in degrading or dissolving the water soluble strip and/or increase the activity of the one or more actives. The water soluble film can be used for a variety of applications such as a hard surface cleaning strip, dishwashing strip, laundry cleaning strip, stop removing strip, drain unclogging strip, toilet bowl cleaning strip and the like. The water soluble strip eliminates the need to purchase and store numerous containers and/or heavy containers of cleaner that take up large amounts of shelf space. | 2012-10-11 |
20120258903 | SPRAYABLE LIQUID ABRASIVE CLEANSER WITH POLYETHYLENE GLYCOL - Liquid abrasive cleanser compositions sprayable through conventional manual trigger sprayers comprise a polyalkylene glycol, a nonionic surfactant, a pH adjusting agent, an abrasive, and water, wherein sprayability is made possible by the addition of the polyalkylene glycol. The compositions that are sprayable and acceptable as hard surface cleaners comprise polyethylene glycol as the polyalkylene glycol. The addition of polyethylene glycol having molecular weight of from about 4,000 to about 1,000,000 dramatically increases the sprayer output volume of liquid abrasive compositions having greater than or equal to 10 wt. % calcium carbonate. Addition of polyethylene glycol of molecular weight of from about 4,000 to about 100,000 converts otherwise non-sprayable liquid abrasive compositions into reliably sprayable compositions. | 2012-10-11 |
20120258904 | USE OF POLYETHYLENE GLYCOL TO CONTROL THE SPRAY PATTERN OF SPRAYABLE LIQUID ABRASIVE CLEANSERS - Liquid abrasive cleanser compositions sprayable through conventional manual trigger sprayers comprise a polyalkylene glycol, a nonionic surfactant, a pH adjusting agent, an abrasive, and water, wherein sprayability is made possible by the addition of the polyalkylene glycol. The compositions that are sprayable and acceptable as hard surface cleaners comprise polyethylene glycol as the polyalkylene glycol. The addition of polyethylene glycol having molecular weight of from about 4,000 to about 1,000,000 dramatically increases the sprayer output volume of liquid abrasive compositions having greater than or equal to 10 wt. % calcium carbonate. Addition of polyethylene glycol of molecular weight of from about 4,000 to about 100,000 converts otherwise non-sprayable liquid abrasive compositions into reliably sprayable compositions. Addition of PEG having molecular weight from about 4,000 to about 100,000 also provides a method for controlling the spray pattern of sprayable liquid abrasive compositions, in particular a method for optimizing the diameter of a conical spray pattern produced from a manual trigger sprayer having a conical spray nozzle. | 2012-10-11 |
20120258905 | VITAMIN RECEPTOR DRUG DELIVERY CONJUGATES FOR TREATING INFLAMMATION - Described herein are compositions, methods, compounds, conjugates, and kits for use in targeted drug delivery using drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations, such as inflammatory cells. | 2012-10-11 |
20120258906 | USE OF PEPTIDES AS ANTIDANDRUFF AGENTS - The present invention relates to compositions comprising peptides with antidandruff activity. The invention also relates to the use of these peptides as antidandruff agents, or in methodes for treating dandruff. | 2012-10-11 |
20120258907 | TREATMENT OF FUNGAL AND/OR PROTIST INFECTIONS - The present invention relates to the use of a polypeptides, comprising repeats of a peptide derived from a Heparan Sulphate Proteoglycan (HSPG) receptor binding region of an apolipoprotein, for treating or preventing a fungal and/or protist infection. The invention further relates to the use of such peptides for treating or preventing the contamination of surfaces or objects with such peptides. | 2012-10-11 |
20120258908 | OLIGOADENYLATE SYNTHETASE (OAS) - The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention. | 2012-10-11 |
20120258909 | Solid Compositions - The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. | 2012-10-11 |
20120258910 | NOVEL BACILLUS THURINGIENSIS INSECTICIDAL PROTEINS - The invention pertains to novel insecticidal compounds derived from | 2012-10-11 |
20120258911 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS - The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents. | 2012-10-11 |
20120258912 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR DELIVERING SUCH COMPOSITIONS - The present invention provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a conjugate having a degradable linkage. The conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods for delivering such compositions are also provided. | 2012-10-11 |
20120258913 | GLUCOPYRANOSIDE COMPOUND - A compound of the formula: | 2012-10-11 |
20120258914 | COACERVATION PROCESS - Methods of forming compositions for the sustained release of water soluble active agents, including biologically active polypeptides and products produced by the process are described. Improved product characteristics and ease of scale-up can be achieved using a novel coacervation process wherein at least one coacervation agent is added to the mixture comprising the active agent and the polymer in at least two distinct stages. | 2012-10-11 |
20120258915 | Proteolysis Resistant Active VEGF - The invention relates to endothelial growth factor (VEGF) in which the alanine at AA position 111 is replaced by proline. The arginine at AA position 110 may moreover be replaced by another amino acid. The invention also relates to derivatives of the VEGF according to the invention, nucleic acids, expression systems, medicaments and the use of the VEGF mutants of the invention for the treatment of chronic wounds. | 2012-10-11 |
20120258916 | OPHTHALMIC PREPARATIONS BASED ON BDNF (BRAIN-DERIVED NEUROTROPHIC FACTOR) AND THEIR USE - Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function. | 2012-10-11 |
20120258917 | Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease - The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent. | 2012-10-11 |
20120258918 | Polypeptoid pulmonary surfactants - The present invention provides spreading agents based on sequence-specific oligomers comprising a peptoid, a peptide-peptoid chimera, a retropeptoid or a retro(peptoid-peptide) chimera, and methods for using the same, including for the treatment of respiratory distress of the lungs. The spreading agents are sequence-specific oligomers, including retrosequence-specific oligomers, based on a peptide backbone, that are designed as analogs of surfactant protein-B or surfactant protein-C. | 2012-10-11 |
20120258919 | Collagen peptide, dipeptide and malady inhibitor - A problem that the present invention is to solve is to provide: a main body of a peptide molecule which is effective for inhibition of various maladies such as osteoporosis, osteoarthritis and pressure ulcer, particularly, a dipeptide which is easy to absorb into a body in an intestine; a collagen peptide which comprises the dipeptide as an essential dipeptide; and a malady inhibitor which comprises the dipeptide as an essential effective component. As a means of solving such a problem, a collagen peptide according to the present invention is characterized by comprising a dipeptide having a structure of Hyp-Gly as an essential dipeptide. A dipeptide according to the present invention is characterized by having a structure of Hyp-Gly. A malady inhibitor according to the present invention is characterized by comprising a dipeptide having a structure of Hyp-Gly as an essential effective component. | 2012-10-11 |
20120258920 | PEPTIDES AND APTAMERS THEREOF AS SPECIFIC MODULATORS OF MUTANT P53 FUNCTION - Mutations in the p53 tumor suppressor gene are frequently found in human tumors and mutant p53 proteins actively collaborate with tumor progression. Interfering with mutant p53 function may represent a valid strategy to block tumor growth and development of aggressive phenotypes. As a consequence of the characteristic of peptide aptamers (PAs) to efficiently and selectively bind a target protein, they are able to interfere with its function and in its ability to interact with other partners. In the present application isolated peptides and aptamers thereof able to interact with structural and conformational p53 mutants within the region of the wild-type p53 DNA binding core domain comprised from amino acids 74 to amino acids 298 using the yeast two-hybrid method are disclosed. These PAs are able to efficiently recognize several different p53 point mutants but not wild-type p53. Therefore the peptides and aptamers identified can be useful as inhibitors of mutant p53-associated pro-oncogenic functions for anticancer therapy or as diagnostic tools for mut-p53 or wild-type p53 or as template for designing new peptido-mimetic drugs able to specifically target tumor cells. | 2012-10-11 |
20120258921 | PEPTIDES FOR THE TREATMENT OF HEARING - Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-α secretion through interaction with toll-like receptor signaling pathways. Experiments are described illustrating the efficacy of the compounds in treating otitis media, noise-induced hearing loss, age-related hearing loss, and improvement of ordinary hearing. | 2012-10-11 |
20120258922 | SYNERGISTIC INHIBITION OF LOW-DENSITY LIPOPROTEIN OXIDATION - The invention provides use of a composition comprising a plant, plant parts, and extracts thereof having high levels of glucoraphanin and/or sulforaphane and tocopherols. Also provided are glucoraphanin and/or sulforaphane, in combination with tocopherols, where the overall composition synergistically inhibits oxidation of low-density lipoproteins. Methods of producing a food from such a plant are also provided. | 2012-10-11 |
20120258923 | BIOACTIVITY COMPOSITION OF Reevesia formosana - A series cardenolide derivatives including structure of formula I from the root of | 2012-10-11 |
20120258924 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM - Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system. | 2012-10-11 |
20120258925 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS - Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): | 2012-10-11 |
20120258926 | FORMULATIONS OF ACADESINE - This invention provides a buffered solution comprising acadesine, as well as compositions, formulations and kits containing said solution. The solution, compositions, formulation, and kits can be used to prevent morbidity/mortality in a patient or to treat an ischaemic condition, a condition regulated by adenosine, or a condition associated with reduced blood flow to a tissue in a patient. | 2012-10-11 |
20120258927 | INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 2012-10-11 |
20120258928 | NUCLEOSIDE CYCLICPHOSPHATES - Cyclic phosphate of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof, represented by the following structure: | 2012-10-11 |
20120258929 | AGENT THAT MODULATES PHYSIOLOGICAL CONDITION OF PESTS, INVOLVED IN INSECT PEPTIDYL-DIPEPTIDASE A ACTIVITY - The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect peptidyl-dipeptidase A; a method for assaying pesticidal activity of a test substance, which comprises a step of measuring the activity of a peptidyl-dipeptidase A in a reaction system in which the peptidyl-dipeptidase A contacts with a test substance, and the like. | 2012-10-11 |
20120258930 | The Improvement of Gastrointestinal Health, Immunity and Performance by Dietary Intervention - This invention relates to the improvement of gastrointestinal health, immunity and performance by direct dietary intervention with a composition comprising a glucan and/or a fucan, and relates in particular to the transfer of associated health benefits to offspring via glucan and/or a fucan supplementation of the maternal diet. Accordingly the present invention provides a composition comprising at least one glucan, at least one fucan, or at least one glucan and at least one fucan for use in improving or maintaining the gastrointestinal health or function of a progeny of a maternal animal by administration to the maternal animal, and a method for improving or maintaining the gastrointestinal health or function of a progeny of a maternal animal, the method comprising administering a composition comprising at least one glucan, at least one fucan, or at least one glucan and at least one fucan to the maternal animal. | 2012-10-11 |
20120258931 | Regimens for Intra-Articular Viscosupplementation - The invention provides viscosupplementation methods for treating osteoarthritis and joint injury with HA-based viscosupplements, particularly viscosupplements with an intra-articular residence half-life shorter than 3 weeks. Viscosupplements for use in the methods of the invention may be further characterized in that they contain less than 20 mg/ml HA, at least 5% (w/w) of which is in a gel form, such as, e.g., hylan B. In an illustrative embodiment, hylan G-F 20 (Synvisc®) is administered in a single intra-articular knee injection of 6±2 ml. | 2012-10-11 |
20120258932 | COMBINATION OF POLYCHITOSAMINE AND HMG-COA REDUCTASE INHIBITOR FOR HYPERLIPIDEMIA - Combinations of therapeutic compounds for prophylaxis or treatment of hyperlipidemia and hyperlipidemia related disorders, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The combinations are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal. The methods of the preferred embodiments comprise administering to a mammal a first amount of polychitosamine and a second amount of an HMG-CoA reductase inhibitor (statin). | 2012-10-11 |
20120258933 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof. | 2012-10-11 |
20120258934 | FOSFOMYCIN PHARMACEUTICAL COMPOSITION - The present invention relates to a solid fosfomycin pharmaceutical composition stable in front the coloration, suitable for diabetics and not entailing gastrointestinal problems. | 2012-10-11 |
20120258935 | PROCESS FOR PREPARATION OF HIV PROTEASE INHBITORS - A process for the synthesis of bisfuran intermediates useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed | 2012-10-11 |
20120258936 | INOSITOL HEXAKISPHOSPHATE ANALOGS AND USES THEREOF - Provided herein are analog and derivative compounds of inositol hexakisphosphate effective to treat a | 2012-10-11 |
20120258937 | Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis - Methods for inhibiting estrogen hormone-induced pulmonary metastasis of smooth muscle cells that are capable of pulmonary metastasis comprise antagonizing the estradiol receptor on the smooth muscle cells such that pulmonary metastasis of the cells is inhibited. | 2012-10-11 |
20120258938 | Enzymatic Production or Chemical Synthesis and Uses for 5,7-Dienes and UVB Conversion Products Thereof - Provided herein are steroidal compounds that are androsta-5,7-dienes or pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof and cholecalciferol derivatives hydroxylated at one or more of C1, C17, C20, C23, C24, C25, and C26 which includes pharmaceutical, cosmeceutical or nutraceutical compositions of the steroidal compounds as shown in Tables 1A, 2A and 3. Also provided is a method for producing hydroxylated metabolites of cholecalciferol via CYP11A1, CYP24, CYP27A1, or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C1 or C20 or other position of the sidechain of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced. Methods are provided for inhibiting proliferation of either a normally or abnormally proliferating cell, for modifying immune activity, or for treating a condition associated with the proliferating or quiescent cell or immune cells by contacting the cell with or administering any of the compounds described herein. | 2012-10-11 |
20120258939 | PHARMACEUTICAL MANUFACTURING PROCESS - The present invention provides a method for preparing a sterile suspension of a glucocorticosteroid. The glucocorticosteroids used in the invention are preferably antiinflammatory glucocorticosteroids. By making the last stage of product preparation be the sterilization process, the potential for contamination during manufacture and heat degradation of products is greatly reduced. | 2012-10-11 |
20120258940 | METHOD FOR TREATING HAEMATOLOGICAL CANCERS - The present invention relates to a combination which comprises (a) a FGFR inhibitor and (b) a glucocorticoid receptor modulator, or a pharmaceutical acceptable salt thereof; the use of such a combination for the preparation of a medicament for the treatment of haematological cancers; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human. | 2012-10-11 |
20120258941 | 17-HYDROXY-17-PENTAFLUORETHYL-ESTRA-4,9(10)-DIEN-11-ARYL DERIVATIVES, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF FOR TREATING DISEASES - The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-aryl derivatives of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception. | 2012-10-11 |
20120258942 | DEVICE FOR TRANSDERMAL ADMINISTRATION OF DRUGS INCLUDING ACRYLIC POLYMERS - A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent. | 2012-10-11 |
20120258943 | FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF - The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5. | 2012-10-11 |
20120258944 | ANTIOXIDANTS FOR USE IN THERAPY - Compounds based on the following structures: wherein each of R1, R2, R3 and R4 is independently selected from: hydrogen, alkyl, and substituted alkyl; and each of R5, R6 and R7 is independently selected from: hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, N,N-dialkylamino, substituted N,N-dialkylamino, N-monoalkylamino, substituted N-monoalkylamino, and electron-donating substituents are useful in the treatment of disorders or conditions caused by or involving free radical-mediated or oxidative tissue damage. | 2012-10-11 |
20120258945 | Association Between Ferroquine and an Artemisinine Derivative for Treating Malaria - This invention is directed to methods for the treatment and prevention of malaria comprising administering a combination of ferroquine, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and an artemisinin derivative, and to pharmaceutical compositions comprising such combination. | 2012-10-11 |
20120258946 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands - Substituted phenylureas and phenylamides, processes for their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds for preparing pharmaceutical compositions. | 2012-10-11 |
20120258947 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS - Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders. | 2012-10-11 |
20120258948 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents - The present invention is directed to a new class of hydroxamic acid derivatives of formula I, | 2012-10-11 |
20120258949 | SPIROCYCLIC DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS - This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m cannot be both 1; R is hydrogen; C | 2012-10-11 |
20120258950 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS - The present invention relates to compounds of Formula (I) | 2012-10-11 |
20120258951 | NOVEL ANTIPLATELET AGENT - The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I: | 2012-10-11 |
20120258952 | Substituted N-(1H-Indazol-4-yl)Imidazo[1,2-a]Pyridine-3-Carboxamide Compounds as cFMS Inhibitors - Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R | 2012-10-11 |
20120258953 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture - The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK-transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer. | 2012-10-11 |
20120258954 | ArylSulfonamide Based Matrix Metalloprotease Inhibitors - The present invention provides a compound of formula (I): | 2012-10-11 |
20120258955 | BICYCLIC THIAZOLES AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved. | 2012-10-11 |
20120258956 | USE OF A SPIROLIDE, ANALOGUES AND DERIVATIVES FOR TREATING AND/OR PREVENTING PATHOLOGICAL CONDITIONS LINKED TO THE TAU AND BETA-AMYLOID PROTEINS - The present invention is in the field of biomedicine. Specifically, it relates to the use of a spirolide compound with the chemical structure: | 2012-10-11 |
20120258957 | HETEROCYCLIC DERIVATIVES - The present invention relates to a heterocyclic derivative according to formula I | 2012-10-11 |
20120258958 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2012-10-11 |
20120258959 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA. | 2012-10-11 |
20120258960 | NOVEL MULTIFUNCTIONAL PEPTIDASE INHIBITORS, ESPECIALLY FOR MEDICAL USE - The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formula (1) in medicine. | 2012-10-11 |
20120258961 | 4-AMINO-1,3-THIAZINE OR OXAZINE DERIVATIVE - The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R | 2012-10-11 |
20120258962 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS - The present invention provides 4-(3-Amino-phenyl)-5,6-dihydro-4H-[1,3]oxazin-2-ylamines of formula I | 2012-10-11 |
20120258963 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS - The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. | 2012-10-11 |
20120258964 | 2-HETEROARYL CARBOXAMIDES - The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. | 2012-10-11 |
20120258965 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS - The invention relates to N-hydroxylsulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxylsulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxylsulfonamide derivatives. | 2012-10-11 |
20120258966 | PHARMACEUTICAL COMPOUNDS - Fused pyrimidines of formula (I): | 2012-10-11 |
20120258967 | PI3 KINASE INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2012-10-11 |
20120258968 | 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY - The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein
| 2012-10-11 |
20120258969 | VIRAL INHIBITORS - Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A), | 2012-10-11 |
20120258970 | Compositions and Methods for the Treatment of Drug-Induced Hand-Foot Syndrome - The present invention provides methods of treating, ameliorating or preventing hand-foot syndrome in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a phosphodiesterase inhibitor. | 2012-10-11 |
20120258971 | THERAPEUTIC AGENT FOR CHRONIC PAIN - This invention provides a novel therapeutic agent for chronic pain. The therapeutic agent for chronic pain comprises aripiprazole as an active ingredient. | 2012-10-11 |
20120258972 | Composition and Methods for Treating Hair Loss - A method for treating hair loss caused by androgenic alopecia and/or male pattern baldness. The method, which not only slows hair loss but causes hair re-growth, includes approximately daily application to a subject's scalp of a novel composition comprising finasteride (Propecia® or Proscar®), dutasteride (Avodart®), and minoxidil (Rogaine®) as active ingredients in a hypoallergenic cream-based vehicle, preferably coupled with daily ingestion of 1 mg per day of finasteride (Propecia® or Proscar®), application to the scalp of 5% minoxidil (Rogaine®) foam approximately once per day, and use of a ketoconazole-containing shampoo (e.g., Nizoral®) approximately 2-3 times per week. The method described herein also resolves scalp dermatitis in atopic subjects suffering therefrom. A method for making the novel composition is also provided. | 2012-10-11 |
20120258973 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES - The invention relates to compound of the formula (I′) in which the substituents are as defined in the specification; in free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it. | 2012-10-11 |
20120258974 | USE OF A2B ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING HEART FAILURE AND ARRHYTHMIA IN POST-MYOCARDIAL INFARCTION PATIENTS - Provided are methods of improving the cardiac condition of post-myocardial infarction (MI) patients and reducing cardiovascular death and hospitalization due to heart failure or arrhythmias, by administering a therapeutically effective amount of an A | 2012-10-11 |
20120258975 | Potent Small Molecule Inhibitors of Autophagy, and Methods of Use Thereof - Certain aspects of the invention relates to small molecule autophagy inhibitors of the formula (I), and their use for treatment and prevention of cancers and acute pancreatitis. As disclosed herein, a small molecule inhibitor of autophagy was been identified from an image-based screen in a known bioactive library. It was found that this autophagy inhibitor functions by promoting the degradation of type III PI3 kinase complex which is required for initiating autophagy. Medicinal chemistry studies led to small molecular autophagy inhibitors with improved potency and selectivity. (I) | 2012-10-11 |
20120258976 | CRYSTALLINE PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS - The present invention discloses novel crystalline and non-crystalline forms of 3-((3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-pip-eridin-1-yl)-3-oxopropionitrile, pharmaceutical composition containing the same, preparations thereof and the uses thereof. | 2012-10-11 |
20120258977 | INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 2012-10-11 |
20120258978 | NITROGEN-CONTAINING SIX-MEMBERED AROMATIC RING DERIVATIVES AND PHARMACEUTICAL PRODUCTS CONTAINING THE SAME - Compounds of Formula (I) promote axonal outgrowth angiogenesis and can therefore be used to reduce central nerve injuries such as head injury and spinal cord injury, cerebral infarction, ischemic heart diseases, peripheral arterial occlusive diseases, or after-effects of these diseases. | 2012-10-11 |
20120258979 | SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF - The present disclosure relates to a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). | 2012-10-11 |
20120258980 | Antibacterial Agent for Drug-Resistant Bacteria, Method for Screening for Same, and Use of Same - A method for treating an individual infected with drug-resistant bacteria resistant to at least one drug, the method including: administering to the individual an antibacterial agent for drug-resistant bacteria which comprises at least one of a nybomycin and a derivative thereof, wherein the antibacterial agent for drug-resistant bacteria is effective to the drug-resistant bacteria resistant to at least one drug. | 2012-10-11 |
20120258981 | Process for the Synthesis of Quaternary Amine Compounds - The invention relates to a process for the synthesis of quaternized compounds of formula: | 2012-10-11 |
20120258982 | ADAMANTYL COMPOUNDS - The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: | 2012-10-11 |
20120258983 | Pharmaceutical Composition and Administrations Thereof - The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention. | 2012-10-11 |
20120258984 | 5-HTP COMBINATION THERAPY - The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor. The present invention also provides a pharmaceutical composition comprising (i) a subclinical dose of a serotonin reuptake inhibitor; and (ii) 5-hydroxytryptophan. | 2012-10-11 |
20120258985 | STABILIZED POLYMERIC THIOL REAGENTS - Disclosed are water soluble polymeric conjugates comprising the structure POLY-[Y—S—S-A] | 2012-10-11 |
20120258986 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF - The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic). | 2012-10-11 |
20120258987 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 2012-10-11 |
20120258988 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES - A therapeutic or prophylactic agent for diabetes includes a thiazolidine derivative as a PPAR-γ agonist as an effective component which exhibits a reduced side effect of the PPAR-γ agonist. The therapeutic or prophylactic agent for diabetes includes a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent exhibits a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists, the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes. | 2012-10-11 |
20120258989 | USE OF SUCCINATE DEHYDROGENASE INHIBITORS FOR EXTENDING SHELF LIFE OF FRUITS AND VEGETABLES - The present invention relates to the use of succinate dehydrogenase Inhibitors for extending shelf life and storage stability of fruits and vegetables, to a method for extending shelf life of fruits and vegetables by applying a succinate dehydrogenase inhibitor to the crops prior to the harvest of the fruits or vegetables and to a fruit or vegetable treated with a succinate dehydrogenase Inhibitor. | 2012-10-11 |
20120258990 | PYRAZOLE DERIVATIVES - The present invention relates to heterocyclic compounds of formula (I) which have microbiocidal activity, in particular fungicidal activity: formula (I) wherein G | 2012-10-11 |
20120258991 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG - A method of treating a cancer selected from the group consisting of breast cancer, pancreatic cancer, kidney cancer, prostate cancer, medulloblastoma, rhabdomyosarcoma, Ewing sarcoma, liposarcoma, multiple myeloma or leukemia. An effective amount of 5-(4-(6-(4-amino-3,5-dimethyl-phenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy)-benzyl)-thiazolidine-2,4-dione.dihydrochloride is administered to a patient having said cancer. | 2012-10-11 |
20120258992 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS - The invention relates to compounds having the formula: | 2012-10-11 |
20120258993 | NON-NATURAL MACROCYCLIC AMIDE HDAC6 INHIBITOR COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS - The present invention relates to novel amide compounds of formula I, and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC6 is responsive, and the pharmaceutical composition containing such compounds. | 2012-10-11 |
20120258994 | Preparation and Use of (+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane In The Treatment of Conditions Affected by Monoamine Neurotransmitters - The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and their use alone or in combination with additional psychotherapeutic compositions in the treatment of conditions affected by monoamine neurotransmitters, including treatment of refractory individuals. | 2012-10-11 |
20120258995 | New Indolinone Protein Kinase Inhibitors - The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer. | 2012-10-11 |